Debt-to-equity of Vor Biopharma Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vor Biopharma Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Vor Biopharma Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -118%, a 394% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Vor Biopharma Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -118% -158% -394% 30 Sep 2025
Q2 2025 -145% -179% -533% 30 Jun 2025
Q1 2025 53% +24% +85% 31 Mar 2025
Q4 2024 45% +20% +81% 31 Dec 2024
Q3 2024 40% +18% +80% 30 Sep 2024
Q2 2024 34% +11% +49% 30 Jun 2024
Q1 2024 29% +4.8% +20% 31 Mar 2024
Q4 2023 25% +1.1% +4.4% 31 Dec 2023
Q3 2023 22% +0.24% +1.1% 30 Sep 2023
Q2 2023 23% +5.3% +30% 30 Jun 2023
Q1 2023 24% +11% +82% 31 Mar 2023
Q4 2022 24% +13% +124% 31 Dec 2022
Q3 2022 22% +6.9% +46% 30 Sep 2022
Q2 2022 17% 30 Jun 2022
Q1 2022 13% 31 Mar 2022
Q4 2021 11% 31 Dec 2021
Q3 2021 15% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.